Authors: Hubl, D Kleinlogel, H Frohlich, L Weinandi, T Maurer, K Holstein, W Czekalla, J Dierks, T

Citation: D. Hubl et al., Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine, PSYCHOPHAR, 158(3), 2001, pp. 281-288

Authors: Czekalla, J Beasley, CM Dellva, MA Berg, PH Grundy, S

Citation: J. Czekalla et al., Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis, J CLIN PSY, 62(3), 2001, pp. 191-198

Authors: Czekalla, J Kollack-Walker, S Beasley, CM

Citation: J. Czekalla et al., Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics, J CLIN PSY, 62, 2001, pp. 35-40

Authors: Braus, DF Schmitt, A Czekalla, J Severa, L

Citation: Df. Braus et al., Therapy-resistant psychotic-depressive disorder - Remission with a selective serotonin reuptake inhibitor in combination with olanzapine, CLIN DRUG I, 20(6), 2000, pp. 455-459

Authors: Dittmann, RW Czekalla, J Hundemer, HP Linden, M

Citation: Rw. Dittmann et al., Efficacy and safety findings from naturalistic fluoxetine drug treatment in adolescent and young adult patients, J CH AD PSY, 10(2), 2000, pp. 91-102

Authors: Volz, HP Riehemann, S Maurer, I Smesny, S Sommer, M Rzanny, R Holstein, W Czekalla, J Sauer, H

Citation: Hp. Volz et al., Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: A P-31 chemical shift spectroscopic-imaging study, BIOL PSYCHI, 47(11), 2000, pp. 954-961